GlassScriptPhysician profile
Jessica E Mckenzie
NPI 1174084396
$2,156.51
in general payments reported to CMS, 2019-2025
22 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $182 · 2023: $258 · 2024: $189 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $935 · Food and Beverage: $915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $934.63 |
| Food and Beverage | $915.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,137.71 | 2025 | Intellis Adaptivestim |
| Abbvie INC. | $189.07 | 2022-2023 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Sumitomo Pharma America, INC. | $112.00 | 2023-2025 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $108.92 | 2023-2025 | Phexxi, Solosec, Phexx |
| Amarin Pharma, INC. | $75.06 | 2022 | |
| Sage Therapeutics, LLC | $56.34 | 2025 | Zurzuvae |
| Pfizer INC. | $53.74 | 2022-2024 | |
| Astellas Pharma US INC | $46.67 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $32.90 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Baxter Healthcare | $28.79 | 2025 | Perclot |
| Dexcom, INC. | $23.70 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $21.63 | 2022 | |
| Millicent US INC | $21.63 | 2025 | Intrarosa |
| Axsome Therapeutics, INC. | $19.36 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.06 | 2023 | Evenity, Prolia |
| Exeltis, USA INC. | $18.83 | 2024 | Slynd |
| Supernus Pharmaceuticals, INC. | $16.50 | 2025 | Qelbree |
| Scynexis, INC. | $16.29 | 2022 | |
| Lilly USA, LLC | $15.21 | 2022 | |
| Melinta Therapeutics, LLC | $12.67 | 2022 | |
| Organon LLC | $5.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.